title: Surgical debridement alone does not adequately reduce planktonic bioburden in chronic lower extremity wounds.
abstract: OBJECTIVE
  It is commonly believed that sharp surgical debridement provides adequate bacteria control for local wound beds, despite limited supporting scientific evidence. We undertook a prospective study to evaluate the reduction in planktonic bacteria pre- and post-operative debridement in critically colonised wounds.
  
  
  METHODS
  Twelve patients, corresponding to 14 wounds, underwent debridement with either hydrodebridement or sharp steel debridement with pulse irrigation. Wound quantitative tissue cultures were taken pre- and post-debridement. There was no significant difference in wound aetiology or surface area between the two groups.
  
  
  RESULTS
  TThe bacterial counts before debridement were 1×107 colony-forming units per gram (CFU/g) in the hydrodebridement group vs 1.4×107 CFU/g in the sharp debridement group; and 2.5×106 CFU/g (hydrodebridement) vs 7.5×105 CFU/g (sharp) after debridement (p=0.41). The total bacteria reduction was 7.5×106 CFU/g after hydrodebridement vs 1.3×107 CFU/g after sharp steel debridement (p=0.37). The mean percentage of bacteria killed from baseline was 75% by hydrodebridement and 93% killed by sharp debridement (p<0.05).
  
  
  CONCLUSIONS
  Extensive operative debridement using either modality does not provide adequate immediate reduction in wound planktonic bioburden. However, all wounds appeared clinically appropriate for closure after debridement and postoperative antibacterial therapy. Postoperative antibacterial therapy may be imperative in cases of critically colonised wounds to achieve good outcomes.
  
  
  BACKGROUND
  The senior author receives research grant support from Healthpoint Biotherapeutics; KCI; Manuka Honey; Smith & Nephew; Medline Ind., Macrocure; CODA. In addition the senior author is a consultant for: Smith & Nephew and KCI and medical consultant and reviewer for Macrocure. While the study as presented evaluates in part the efficacy of a commercial product from Smith & Nephew, no industry support for this study was sought or provided.
authors.affiliation: St. Luke's-Roosevelt Hospital Center, New York, United States.
authors.forename: J A
authors.initials: JA
authors.lastname: Schwartz
authors.forename: S G
authors.initials: SG
authors.lastname: Goss
authors.forename: F
authors.initials: F
authors.lastname: Facchin
authors.forename: E
authors.initials: E
authors.lastname: Avdagic
authors.forename: J C
authors.initials: JC
authors.lastname: Lantis
mesh_terms: D000328:Adult; D002908:Chronic Disease; D003646:Debridement; D005260:Female; D018409:Foot Injuries / Q000601:surgery; D006801:Humans; D035002:Lower Extremity / Q000293:injuries*; D008297:Male; D008875:Middle Aged; D010933:Plankton; D011446:Prospective Studies
keywords: VersaJet™; critically colonised; hydrodebridement; lower extremity ulcer; sharp debridement